Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
Trinity Biotech (Nasdaq: TRIB) has received regulatory approval to begin offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic manufacturing transition follows a previous World Health Organization (WHO) approval and represents a crucial milestone in the company's transformation strategy.
The new manufacturing model is designed to deliver three key benefits: expanded gross margins, freed up working capital, and reduced fixed costs. The company has already initiated manufacturing under this new operational framework, which aims to maintain product integrity and regulatory compliance while improving cost-effectiveness and scalability.
Trinity Biotech (Nasdaq: TRIB) ha ottenuto l'autorizzazione regolatoria per avviare la produzione offshore e in outsourcing del suo principale prodotto, il test rapido TrinScreen™ HIV. Questa transizione produttiva, che segue una precedente approvazione dall'Organizzazione Mondiale della Sanità (OMS), costituisce una tappa fondamentale nella strategia di trasformazione dell'azienda.
Il nuovo modello produttivo è concepito per offrire tre vantaggi principali: margini lordi maggiori, liberamento di capitale circolante e riduzione dei costi fissi. L'azienda ha già avviato la produzione secondo questo nuovo assetto operativo, con l'obiettivo di preservare l'integrità del prodotto e la conformità normativa, migliorando al contempo efficienza dei costi e scalabilità.
Trinity Biotech (Nasdaq: TRIB) ha recibido la aprobación regulatoria para iniciar la fabricación offshore y subcontratada de su principal prueba rápida, TrinScreen™ HIV. Esta transición de producción, tras una aprobación previa de la Organización Mundial de la Salud (OMS), representa un hito clave en la estrategia de transformación de la compañía.
El nuevo modelo de fabricación está diseñado para aportar tres beneficios clave: márgenes brutos ampliados, liberación de capital de trabajo y reducción de costos fijos. La empresa ya ha comenzado la producción bajo este nuevo marco operativo, buscando mantener la integridad del producto y el cumplimiento regulatorio mientras mejora la rentabilidad y la escalabilidad.
Trinity Biotech (Nasdaq: TRIB)가 주력 제품인 TrinScreen™ HIV 신속 검사의 해외 및 외주 생산을 시작할 수 있는 규제 승인 을 받았습니다. 이번 제조 전환은 세계보건기구(WHO)의 이전 승인에 이은 것으로, 회사의 전환 전략에서 중요한 이정표입니다.
새 제조 모델은 세 가지 핵심 혜택을 제공하도록 설계되었습니다: 확대된 총이익률, 운전자본 확보, 그리고 고정비 축소. 회사는 이미 이 새로운 운영 체계에 따라 생산을 시작했으며, 제품의 무결성과 규제 준수를 유지하면서 비용 효율성과 확장성을 개선하는 것을 목표로 하고 있습니다.
Trinity Biotech (Nasdaq: TRIB) a obtenu l'autorisation réglementaire de lancer la fabrication offshore et externalisée de son test rapide phare, le TrinScreen™ HIV. Cette transition de production, après une approbation antérieure de l'Organisation mondiale de la santé (OMS), constitue une étape clé de la stratégie de transformation de la société.
Le nouveau modèle de fabrication vise à apporter trois bénéfices majeurs : marges brutes accrues, libération de fonds de roulement et réduction des coûts fixes. La société a déjà engagé la production selon ce nouveau cadre opérationnel, visant à préserver l'intégrité du produit et la conformité réglementaire tout en améliorant la rentabilité et la capacité de montée en charge.
Trinity Biotech (Nasdaq: TRIB) hat die behördliche Genehmigung erhalten, die Offshore- und Fremdproduktion seines Flaggschiff-Produkts, des TrinScreen™ HIV Schnelltests, aufzunehmen. Dieser strategische Produktionswechsel folgt einer früheren Zulassung durch die Weltgesundheitsorganisation (WHO) und markiert einen wichtigen Meilenstein in der Transformationsstrategie des Unternehmens.
Das neue Produktionsmodell zielt darauf ab, drei zentrale Vorteile zu liefern: erweiterte Bruttomargen, freigesetztes Umlaufkapital und reduzierte Fixkosten. Das Unternehmen hat die Produktion unter diesem neuen Betriebsrahmen bereits gestartet und strebt an, Produktintegrität und regulatorische Compliance zu wahren und gleichzeitig Kosten-effizienz und Skalierbarkeit zu verbessern.
- Regulatory approval received for offshore manufacturing of flagship HIV test
- Expected gross margin expansion through cost-effective manufacturing
- Reduction in fixed costs through outsourced production model
- Working capital optimization potential
- Enhanced manufacturing scalability while maintaining product quality
- Potential risks in transitioning to new manufacturing model
- Dependency on third-party manufacturers
- Possible operational disruptions during transition period
Insights
Trinity Biotech's regulatory approval for offshore HIV test manufacturing should improve margins and capital efficiency while reducing fixed costs.
Trinity Biotech has secured a critical regulatory milestone that transforms their manufacturing strategy for the TrinScreen™ HIV rapid test. This approval enables the company to shift from capital-intensive in-house production to an outsourced model that should yield multiple operational benefits. The TrinScreen™ HIV test is particularly important as it carries World Health Organization (WHO) prequalification status, making it eligible for procurement by international health agencies that serve developing markets where HIV testing remains crucial.
The transition to outsourced manufacturing addresses three key financial challenges simultaneously. First, it should expand gross margins by lowering production costs through more efficient third-party manufacturing. Second, it will free up working capital previously tied to inventory, raw materials, and manufacturing equipment. Third, the company will reduce fixed costs by eliminating the overhead associated with maintaining in-house production facilities.
This operational restructuring represents a classic asset-light strategy that enhances scalability without requiring proportional capital investment. Rather than maintaining expensive manufacturing infrastructure, Trinity can leverage third-party expertise while maintaining quality control through regulatory compliance frameworks. The dual approvals from both the local regulatory authority and previously from the WHO indicate the company has successfully navigated the complex regulatory requirements for this transition while preserving product integrity.
Approval Facilitates Immediate Offshored and Outsourced Manufacturing
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability
Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader Profitability and Growth Objectives
DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the in-country healthcare product regulatory authority has granted the key approval to initiate offshore and outsourced manufacturing of its flagship World Health Organization (WHO) prequalified TrinScreen™ HIV rapid test.
This key approval now enables Trinity Biotech to transition upstream production from its legacy in-house operations to a more cost-effective and scalable outsourced model, while maintaining the highest levels of product integrity and regulatory compliance. Trinity Biotech has now begun manufacturing under this new model, marking a critical milestone in the Company’s transformation strategy. The strategic shift is expected to:
- Expand gross margins.
- Free up working capital.
- Reduce fixed costs, supporting broader profitability and growth objectives.
This latest approval builds on the previously announced WHO approval for the offshored and outsourced upstream manufacturing activities of Trinity Biotech’s high-volume TrinScreen™ HIV rapid test.
“This key regulatory approval is a major step forward in our transformation journey,” said John Gillard, President and Chief Executive Officer of Trinity Biotech. “It builds on our earlier WHO authorization and allows us to fully operationalize our offshore manufacturing model for TrinScreen™ HIV. This transition unlocks significant cost efficiencies, enhances scalability, and positions the Company for long-term financial health.”
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc Susan O’Connor (353)-1-2769800 | RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com |
FAQ
What regulatory approval did Trinity Biotech (TRIB) receive in August 2025?
How will the new manufacturing model affect Trinity Biotech's operations?
What is the strategic importance of this manufacturing transition for TRIB?
Who approved Trinity Biotech's offshore manufacturing activities previously?
What are the main risks associated with Trinity Biotech's manufacturing transition?
